Fig. 1From: Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphomaProgression-free survival (PFS, a) and overall survival (OS, b) of all patients treated either with (N = 45) or without (N = 35) rituximab. Median PFS and OS not reachedBack to article page